Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Anshuman Panda, … , Gyan Bhanot, W. Kimryn Rathmell
Anshuman Panda, … , Gyan Bhanot, W. Kimryn Rathmell
Published August 23, 2018
Citation Information: JCI Insight. 2018;3(16):e121522. https://doi.org/10.1172/jci.insight.121522.
View: Text | PDF
Research Article Immunology Oncology

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

  • Text
  • PDF
Abstract

Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain. We investigated whether abnormal expression of endogenous retroviruses (ERVs) in tumors is associated with local immune checkpoint activation (ICA) and response to ICB. Twenty potentially immunogenic ERVs (πERVs) were identified in ccRCC in The Cancer Genome Atlas data set, and tumors were stratified into 3 groups based on their expression levels. πERV-high ccRCC tumors showed increased immune infiltration, checkpoint pathway upregulation, and higher CD8+ T cell fraction in infiltrating leukocytes compared with πERV-low ccRCC tumors. Similar results were observed in ER+/HER2− breast, colon, and head and neck squamous cell cancers. ERV expression correlated with expression of genes associated with histone methylation and chromatin regulation, and πERV-high ccRCC was enriched in BAP1 mutant tumors. ERV3-2 expression correlated with ICA in 11 solid cancers, including the 4 named above. In a small retrospective cohort of 24 metastatic ccRCC patients treated with single-agent PD-1/PD-L1 blockade, ERV3-2 expression in tumors was significantly higher in responders compared with nonresponders. Thus, abnormal expression of πERVs is associated with ICA in several solid cancers, including ccRCC, and ERV3-2 expression is associated with response to ICB in ccRCC.

Authors

Anshuman Panda, Aguirre A. de Cubas, Mark Stein, Gregory Riedlinger, Joshua Kra, Tina Mayer, Christof C. Smith, Benjamin G. Vincent, Jonathan S. Serody, Kathryn E. Beckermann, Shridar Ganesan, Gyan Bhanot, W. Kimryn Rathmell

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2009 Total
Citations: 13 9 15 27 23 17 9 1 114
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2023 (15)

Title and authors Publication Year
Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma
Shin Kobayashi, Serina Tokita, Katsuyuki Kitahara, Hiromichi Iuchi, Kazuhiko Matsuo, Hidehiro Kakizaki, Takayuki Kanaseki, Toshihiko Torigoe
JCI Insight 2023
Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy
Parab A, Kumar Bhatt L, Omri A
Biomedicines 2023
Endogenous Retrovirus RNA Expression Differences between Race, Stage and HPV Status Offer Improved Prognostication among Women with Cervical Cancer
Alldredge J, Kumar V, Nguyen J, Sanders BE, Gomez K, Jayachandran K, Zhang J, Schwarz J, Rahmatpanah F
International journal of molecular sciences 2023
ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
Chen J, Rebibo D, Cao J, Mok SY, Patel N, Tseng PC, Zhang Z, Yip KY
2023
RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer
Li HT, Jang HJ, Rohena-Rivera K, Liu M, Gujar H, Kulchycki J, Zhao S, Billet S, Zhou X, Weisenberger DJ, Gill I, Jones PA, Bhowmick NA, Liang G
Cell Reports 2023
Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens.
Wolf MM, Rathmell WK, de Cubas AA
Nature reviews. Nephrology 2023
HERVs and Cancer—A Comprehensive Review of the Relationship of Human Endogenous Retroviruses and Human Cancers
Stricker E, Peckham-Gregory EC, Scheurer ME
Biomedicines 2023
Viewing RCC with a DNA methylation lens ENHANCES understanding of ICI resistance
Zhou M, Kim WY
Clinical cancer research 2023
Human endogenous retroviruses in cancer: Oncogenesis mechanisms and clinical implications.
Kitsou K, Lagiou P, Magiorkinis G
Journal of Medical Virology 2023
Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics.
Zhong F, Lin Y, Zhao L, Yang C, Ye Y, Shen Z
British Journal of Cancer 2023
Exploring the Expression of the «Dark Matter» of the Genome in Mesothelioma for Potentially Predictive Biomarkers for Prognosis and Immunotherapy
Felley-Bosco E
Cancers 2023
Endogenous retrovirus group FRD member 1 is a potential biomarker for prognosis and immunotherapy for kidney renal clear cell carcinoma
Wen X, Shen J, De Miglio MR, Zeng D, Sechi LA
Frontiers in Cellular and Infection Microbiology 2023
Proceedings of the inaugural Dark Genome Symposium: November 2022
Boeke JD, Burns KH, Chiappinelli KB, Classon M, Coffin JM, DeCarvalho DD, Dukes JD, Greenbaum B, Kassiotis G, Knutson SK, Levine AJ, Nath A, Papa S, Rios D, Sedivy J, Ting DT
Mobile DNA 2023
The Role of Human Endogenous Retroviruses in Cancer Immunotherapy of the Post-COVID-19 World
Logotheti S, Stiewe T, Georgakilas AG
Cancers 2023
Dysregulated Repeat Element Viral-like Immune Response in Hepatocellular Carcinoma
Coley AK, Lu C, Pankaj A, Emmett MJ, Lang ER, Song Y, Xu KH, Xu N, Patel BK, Chougule A, Nieman LT, Aryee MJ, Ferrone CR, Deshpande V, Franses JW, Ting DT
2023

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts